North America Fetal Bovine Serum Market Size, Share, and COVID-19 Impact Analysis, By Application (Drug Discovery, In-Vitro Fertilization, Vaccine Production, Cell-Based Research, Diagnosis, and Others), By End User (Pharmaceutical & Biotechnology Companies, Contract Research Organizations, Academic and Research Organizations, and Others), and North America Fetal Bovine Serum Market Size Insights, Industry Trends, Forecast to 2035

North America Fetal Bovine Serum Market Size Insights Forecasts to 2035

• The North America Fetal Bovine Serum Market Size Was Estimated at USD 782.6 Million in 2024
• The Market Size is Expected to Grow at a CAGR of Around 14.2% from 2025 to 2035
• The North America Fetal Bovine Serum Market Size is Expected to Reach USD 3372.3 Million by 2035

According to a Research Report Published by Spherical Insights & Consulting, The North America Fetal Bovine Serum Market Size is anticipated to reach USD 3372.3 Million by 2035, growing at a CAGR of 14.2% from 2025 to 2035. The market is driven by an increase in research and development activities related to cell culture in the scientific sectors such as biopharmaceuticals & biotechnology.

Market Overview

Fetal Bovine Serum is a multipurpose medium for several cell types that can simultaneously sustain the growth of both adherent and suspended cultures. It is an essential factor for the cell's development, multiplication, and existence. Its widespread use in the life science industry, particularly to perform research, is one of the primary drivers of the market. Major factors contributing to the growth of the market include the rapid development of countries, an increase in culture media, vaccine production growth, and the regulatory authorities' increasing approval of products. Among the various applications, it is first of all used in the biotechnological research fields, including but not limited to cancer research, biopharmaceutical development, human and animal vaccines, and many other research areas.

The U.S. government, via the National Institutes of Health, is a major stakeholder when it comes to funding, setting aside more than $45 billion for biomedical research in 2023, a significant portion of which goes to cell culture projects. The increased emphasis of the pharmaceutical sectors on research and development is the main reason for the accelerated demand for culture media.

In May 2024, Grifols and UCSD made a collaboration to invent new bioprocessing technologies for FBS. Increasing investments in R&D of drug discovery, targeted medicine, and cell and gene therapies (like CAR-T) are the main reasons for the increasing demand for high-quality FBS.

Report Coverage

This research report categorizes the market for the North America Fetal Bovine Serum Market Size based on various segments and regions, and forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the North America Fetal Bovine Serum Market Size. Recent market developments and competitive strategies, such as expansion, product launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the North America Fetal Bovine Serum Market Size.

Driving Factors

The fetal bovine serum market in North America is driven by biopharmaceuticals & biotechnology witnessed a rise in research and development activities regarding cell culture. R&D activities on the introduction of new biopharmaceuticals have a considerable influence on the rise of the global fetal bovine serum market. The rising areas of application, like personalised medicine, gene therapy, and regenerative medicine, need high-purity and speciality-grade FBS products.

Restraining Factors

The fetal bovine serum market in North America is restrained by the limited access to top-notch raw material sources, which is the result of a few factors, such as the decrease in the U.S. cattle herd and the stringent collection standards, putting pressure on the supply chains. There is a heightened scrutiny and also a greater public awareness of the animal welfare issues since FBS collection mostly entails getting blood from bovine fetuses during the slaughter of pregnant cows.

Market Segmentation

The North America Fetal Bovine Serum Market Size share is categorised into application and end user.

• The cell-based research segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. 

The North America Fetal Bovine Serum Market Size is segmented by application into drug discovery, in vitro fertilization, vaccine production, cell-based research, diagnosis, and others. Among these, the cell-based research segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. In 2024, the cell-based research accounted for the largest segment of the market, representing 33.96% of the total revenue. The U.S. and Canada have a large network of academic and private research institutions, biopharmaceutical companies, and contract research organisations (CROs) that rely on FBS for costly research. Supportive government policies and R&D spending make it possible to invest in cell-based life science projects continuously.

• The pharmaceutical & biotechnology companies segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period.  

Based on end user, the North America Fetal Bovine Serum Market Size is segmented into pharmaceutical & biotechnology companies, contract research organizations, academic and research organizations, and others. Among these, the pharmaceutical & biotechnology companies segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period. The segmental growth is driven by the display exhibits a prosperous speed of innervation, mainly due to simultaneous R&D for biological pharmaceutical drugs and cancer research.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the North America Fetal Bovine Serum Market Size, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborate analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies                                                                                                                              

• RMBIO
• Atlas Biologicals, Inc.
• Bio-Techne Corp
• Danaher Corp
• Thermo Fisher Scientific Inc
• Merck KGaA
• Sartorius AG
• Corning Incorporated
• GE Healthcare
• Atlanta Biologicals Inc.
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at the North America, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the North America Fetal Bovine Serum Market Size based on the below-mentioned segments:

North America Fetal Bovine Serum Market Size, By Application

• Drug Discovery
• In-Vitro Fertilization
• Vaccine Production
• Cell-Based Research
• Diagnosis
• Others

North America Fetal Bovine Serum Market Size, By End User

• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations
• Academic and Research Organisations
• Others